Top Banner Top Banner

1. The American Cancer Society. Liver Cancer 2011.

2. Gu JW, et al. Ethanol stimulates tumor progression and expression of vascular endothelial growth factor in chick embryos. Cancer 2005;103:422-31.

3. Llovet J, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized, placebo-controlled trial (SHARP trial). J Clin Oncol 2007;25;18S (suppl; abstr LBA1).

4. Faivre SJ, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 25 2007;18S (suppl; abstr 3546).

5. Abou-Alfa G, et al. (2007) Preliminary results from a phase 2, randomized, double-blind, study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer 5;259 (suppl; abstr 3500).

6. Accessed July 12, 2010.

7. Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. Journal of Clinical Oncology [early online publication]. January 12, 2009.

8. Brandi G, et al. (2007) Metronomic capecitabine in advanced patients with hepatocellular carcinoma (HCC): Preliminary results. J Clin Oncol 25;18S (suppl; abstr 15163).

9. Bayer/Onyx. Sorafenib Prescribing Information. Available at: Accessed November 26, 2007.

10. System ENABLEā„¢.

Last updated March 1, 2012